Aditxt and Evofem amend merger agreement
Aditxt and Evofem amend merger agreement
Aditxt signs second amendment to arrangement agreement with Appili Therapeutics
Aditxt signs agreement to acquire Appili Therapeutics
4.97MUSD
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US0070251097
CUSIP
-
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
0.00
PEG Ratio
-
Book Value
486.96
Dividend Share
-
Dividend Yield
-
Earnings Share
628.8
Wall Street Target Price
61
EPS Estimate Current Year
0
EPS Estimate Next Year
0
EPS Estimate Current Quarter
0
EPS Estimate Next Quarter
0
Most Recent Quarter
-
Revenue TTM
329,739
Gross Profit TTM
166,936
EBITDA
-33,094,198
Profit Margin
0.00%
Return On Assets TTM
-117.61%
Return On Equity TTM
-3493.63%
Revenue Per Share TTM
12.114
Qtly Revenue Growth YOY
-80.00%
Diluted Eps TTM
628.8
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
0
Price Sales TTM
15.1563
Price Book MRQ
1.0546
Enterprise Value Revenue
69
Enterprise Value EBITDA
0
794.90
1.45%90.52
1.02%207.25
0.79%121.20
0.26%256.40
0.19%525.60
0.00%170.35
0.00%611.01
-2.04%96.13
-1.46%473.46
-0.12%